898258-72-5

Basic information

• Product Name: 2-(piperazin-1-yl)thiazole-5-carbonitrile
• CAS NO: 898258-72-5
• Molecular Weight: 194.26
• Mol File: 898258-72-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-(piperazin-1-yl)thiazole-5-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(piperazin-1-yl)thiazole-5-carbonitrile(898258-72-5)
• EPA Substance Registry System: 2-(piperazin-1-yl)thiazole-5-carbonitrile(898258-72-5)

Safety Data

• Hazardous Substances Data: 898258-72-5(Hazardous Substances Data)

Upstream product

• 1095538-69-4 tert-butyl 4-(5-cyanothiazol-2-yl)piperazine-1-carboxylate 
• 110-85-0 piperazine 
• 440100-94-7 2-bromothiazole-5-carbonitrile 

Downstream Products

• 1095534-94-3 (1R,2R)-N-(1-cyanocyclopropyl)-2-{[4-(5-cyano-1,3-thiazol-2-yl)piperazin-1-yl]carbonyl}cyclohexanecarboxamide 

Relevant articles and documents

2-Substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue and preparation method and application thereof

The invention discloses 2-substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue and a preparation method and application thereof, and particularly, relates to 2-substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue with a formula (I) compound and a preparation method and application thereof, wherein substitutions in the formula (I) compound are defined as in the description. This serial compound can inhibit the activity of glycine transport protein-1 (GlyT1), is useful in treating related diseases in central nerve and psychological fields, for example, schizophrenia (including positive symptoms, negative symptoms and cognitive symptoms), senile dementia, Parkinson's disease and other related psychological diseases, is widely applicable to the drugs for preventing and treating central nerve and psychological diseases, and is expected to be developed into new-generation GlyT1 inhibitors.

CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS

The present invention relates to compounds of formula (I) for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases, including cathepsins B, K, C, F, H, L, O, S, W and X. Of particular interest are diseases associated with Cathepsin K.